TEL AVIV, Israel and WHITE PLAINS, N.Y., May 30, 2013 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce that it will be presenting updates on the Company's business and technology at two key conferences in the month of June.
Orgenesis' CEO, Sav DiPasquale, will present a company overview on June 10, 2013 at the IATI Biomed Conference in Tel Aviv, Israel. This is Israel's premier life science conference showcasing the country's most advanced companies and technologies. Last year's event drew 6,000 industry players, engineers and scientists, with 1,000 participants from 42 countries and more than 3,500 one-on-one meetings.
Prof. Sarah Ferber, Chief Science Officer of Orgenesis, will speak at the International Society for Stem Cell Research ("ISSCR") 11th Annual Meeting on June 14, 2013 in Boston, MA. ISSCR is the largest international interdisciplinary forum dedicated to stem cell science. Prof. Ferber's talk will focus on the mechanism of transdifferentiation and its implementation in autologous cell replacement therapy for diabetic patients.
"We are very pleased to have these two important opportunities to update investors, life science industry participants and cell therapy experts on our progress to-date within the groundbreaking field of transdifferentiation and the promise those advancements may hold for the treatment of diabetes," said Mr. DiPasquale.
About Orgenesis Inc.
Orgenesis (OTCBB:ORGS) is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. For more information visit: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase, our ability to retain key employees and our ability to finance development or satisfy the rigorous regulatory requirements for new medical procedures. Competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.
On Behalf of the Board
Orgenesis Inc.
Vered Caplan, Chairperson